has Server used IP Address with Hostname in Austria. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2003-04-16 (16 years, 6 days) and hosted in Austria, server ping response time 104 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Affiris keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Affiris
2 Affiristic
3 Affiris and booster
4 Affiris ag
5 Affiris ad02
6 Affiris gmbh
7 Affiris pcsk9
8 Affiris vaccine
9 Affiris parkinson's vaccine

Hosting Provider

Latitude: 48.200000762939
Longitude: 16.36669921875
Area Code: 0
Email AbuseNo Emails Found

Listing Websites Same Server

We Found 7 Websites on IP Address in Austria

Find Other Domains on Any IP/ Domain

New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently (33 seconds ago) (31 seconds ago) (3 seconds ago) (15 seconds ago) (1 seconds ago) (7 seconds ago) (18 seconds ago) (18 seconds ago) (26 seconds ago) (37 seconds ago) (2 seconds ago) (10 seconds ago) (4 seconds ago) (10 seconds ago) (24 seconds ago) (17 seconds ago) (16 seconds ago) (6 seconds ago) (3 seconds ago) (1 seconds ago)

Results For Websites Listing

Found 48 Websites with content related to this domain, It is result after search with search engine

Affiris - Official Site

14 May 2018. AFFiRiS Announces Encouraging Long-term Data from a Series of First-in-Human Studies Using AFFITOPE ® PD01A Targeting Oligomeric Alpha-synuclein in Early Parkinson’s Disease Patients.

AFFiRiS AG: Private Company Information - Bloomberg

AFFiRiS AG develops and manufactures peptide-based vaccines for therapeutic treatment of chronic diseases with unmet medical needs. Its development portfolio includes vaccines against Alzheimer

Affiris | The Science of Parkinson's

AFFiRiS is a small biotech company in Vienna (Austria) that has an ongoing clinical trial program for a vaccine (called ‘AFFITOPE® PD01A’) against alpha synuclein. The subjects in the study (22 people with Parkinson’s disease) received four vaccinations – each injection given four-weeks apart – and then the subjects were observed for

A vaccine for Parkinson’s – the AFFiRiS update | The

This week Austrian biotech firm, AFFiRiS AG, made an announcement regarding their experimental immunotherapy/'vaccine' approach for Parkinson's. In their press release, the company provided the results of a long-term Phase I clinical trial testing the tolerability and safety of their treatment AFFITOPE® PD01A. The treatment was found to be safe and well-tolerated in people with…

AFFiRiS AG | LinkedIn

See more information about AFFiRiS AG, find and apply to jobs that match your skills, and connect with people to advance your career. We are a clinical-stage biotechnology company that strives to

AFFiRiS Michael J Fox Foundation Report Positive Results

AFFiRiS announced in a press release that a study on PD01A, a Parkinson’s disease vaccine, has shown positive results. The research, sponsored by the Michael J. Fox Foundation for Parkinson's Research (MJFF), met its primary endpoint as two different doses of PD01A were well tolerated and safe.

Recently Analyzed Sites